NCT00242671

Brief Summary

The twilight phase between being asleep and awake during recovery from anesthesia is a precarious time fraught with risks to the post-operative patient. Hyperventilation accelerates the elimination of inhaled anesthetics but reduces their CO2 blood concentrations which delays their resumption of spontaneous breathing. We previously showed that our method of hyperventilation without affecting the CO2 concentration--which we call IH--accelerates the rate of emergence from anesthesia with isoflurane. In this study we will study the effect of IH on the rate of emergence from Sevoflurane anesthesia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Oct 2005

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2005

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

October 18, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 20, 2005

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2008

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
Last Updated

August 5, 2010

Status Verified

September 1, 2006

Enrollment Period

2.8 years

First QC Date

October 18, 2005

Last Update Submit

August 3, 2010

Conditions

Keywords

general anesthesia, hyperventilation, carbon dioxide, isocapnic hyperponea

Outcome Measures

Primary Outcomes (1)

  • Time to recovery from anesthesia as indicated by time to extubation and rate of change of BIS score

Secondary Outcomes (1)

  • Quality of recovery in the recovery room as indicated by the level of consciousness, incidence of nausea, vomiting, shivering and other phenomena occuring during recovery

Interventions

Eligibility Criteria

Age18 Years - 80 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Elective gynecological procedure
  • ASA I-III
  • Age 18-80 years
  • Signed informed consent

You may not qualify if:

  • ASA IV
  • Patients with contra-indications to Sevoflurane anesthesia or other anesthetics included in the protocol
  • Active smoking, asthma or other history of hyper-reactive airway disease
  • History of chronic obstructive lung disease limiting exercise
  • History of angina, previous myocardial infarction, valvular heart disease, or heart surgery
  • Presence of heart murmurs or neck bruits
  • ECT abnormalities including atrial fibrillation, prolonged P-R interval, prolonged Q-T interval, presence of Q waves in inferior, anterior or lateral leads, criteria for left ventricular hypertrophy, T-wave abnormalities,
  • History of difficult airway access
  • Pulmonary hypertension and/or right ventricle dysfunction
  • History of bulous emphysema, and/or spontaneous pneumothorax
  • History of alcohol or drugs abuse
  • Known history of psychiatric illness and/or medications
  • Patients that required postoperative mechanical ventilation for any reason

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Toronto General Hospital, University Health Network

Toronto, Ontario, M5G 2C4, Canada

Location

MeSH Terms

Conditions

Hyperventilation

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Rita Katznelson, MD

    Toronto General Hospital, University Health Network

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

October 18, 2005

First Posted

October 20, 2005

Study Start

October 1, 2005

Primary Completion

August 1, 2008

Study Completion

December 1, 2008

Last Updated

August 5, 2010

Record last verified: 2006-09

Locations